Astellas advances Phase 3 setidegrasib trial in KRAS G12D pancreatic cancer
Astellas Pharma Inc. is presenting updates for PADCEV with pembrolizumab and late-stage setidegrasib trials in KRAS G12D pancreatic and lung cancers at ESMO 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.